The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel

OBJECTIVE: Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. Most patients are diagnosed at an advanced stage, palliative chemotherapy therefore being the only treatment option. This study was aimed at evaluating the health-related quality of life (HRQoL) of advanced-stage NSCLC patients receiving palliative chemotherapy with carboplatin and paclitaxel. METHODS: This was a multiple case study of advanced-stage NSCLC outpatients receiving chemotherapy at a public hospital in Rio de Janeiro, Brazil. The European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire was used in conjunction with its supplemental lung cancer-specific module in order to assess HRQoL. RESULTS: Physical and cognitive functioning scale scores differed significantly among chemotherapy cycles, indicating improved and worsened HRQoL, respectively. The differences regarding the scores for pain, loss of appetite, chest pain, and arm/shoulder pain indicated improved HRQoL. CONCLUSIONS: Chemotherapy was found to improve certain aspects of HRQoL in patients with advanced-stage NSCLC.

Download Full-text

Association of pretreatment financial toxicity with time to treatment for patients with head and neck carcinoma and lung carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2020.39.28_suppl.131 ◽

2021 ◽

Vol 39 (28_suppl) ◽

pp. 131-131

Author(s):

Sharon Lam ◽

Nicolas Schlecht ◽

Gregory Rosenblatt ◽

Vikas Mehta

Keyword(s):

Quality Of Life ◽

Lung Carcinoma ◽

Small Cell Lung Carcinoma ◽

Treatment Delay ◽

Small Cell ◽

Financial Toxicity ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Younger Age

131 Background: Financial toxicity (FT) describes objective and subjective burden of costs associated with medical care. Patients with head and neck cancer (HNC) and lung carcinoma are acutely impacted by FT, as these cancers disproportionately occur in populations that are poor, unemployed, and/or of minority backgrounds compared to patients with other cancers. Our group recently published results showing delay in time to treatment initiation (TTI) was associated with poorer survival in HNC patients. Another study reported that FT was associated with worse progression-free survival in non-small cell lung cancer patients. In this study, we sought to investigate the association between FT, TTI and clinical outcomes among HNC and lung carcinoma patients, as well as predictors of FT. Methods: A retrospective analysis of 140 patients diagnosed with either HNC or lung carcinoma between January 2007 and March 2018 with quality-of-life data collected prospectively at the time of radiation oncology treatment was conducted. Participants responded to a question about their experience on ‘financial difficulties’ with a 4-point Likert Scale within the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) quality of life assessment. FT was low when patients indicated ‘1’ (not at all) or ‘2’ (a little), and high if patients indicated ‘3’ (quite a bit), and ‘4’ (very much). Chi-square test and Student’s t-test were used to compare characteristics of patients with and without FT. The association between FT and TTI and survival outcomes were analyzed using the Kaplan-Meier methods and Cox proportional-hazards regression models. Results: The study sample included 70 patients with HNC (mean [SD] age, 64.3 [12.0]; 62.7% male) and 70 patients with lung carcinoma (mean [SD] age, 69.1 [10.2]; 38.0% male). Over half (N = 80, 55.2%) reported experiencing financial toxicity (64% HNC vs. 45.7% lung carcinoma). Younger age (< 60 years), having Medicaid, and having small-cell lung carcinoma were associated with greater FT (p = 0.049, p = 0.042, p = 0.034, respectively). Patients who reported having poorer health and quality of life also experienced greater FT (p = 0.030, p = 0.016, respectively). HNC patients who experienced greater FT were less likely to experience treatment delay (p = 0.035). After adjusting for age, sex, ethnicity, tumor site, and tumor stage, FT was associated with worse survival outcomes in all patients (HR = 1.52, 95% CI 1.06-2.19). Conclusions: Greater FT was associated with younger age, having Medicaid, and having small-cell lung carcinoma. HNC patients who experienced greater FT were less likely to experience treatment delay, which suggests that delay may not be a causative factor for the worsened survival seen with patients who report FT.

Download Full-text

Analysis of Young and Elderly Advanced Stage Nonsmall-Cell Lung Carcinoma Cases

Southern Medical Journal ◽

10.1097/smj.0b013e3181b66b11 ◽

2009 ◽

Vol 102 (10) ◽

pp. 1019-1022 ◽

Cited By ~ 3

Author(s):

Sibel Arinc ◽

Ferah Ece ◽

Muyesser Ertugrul ◽

Nuray Erdal ◽

Ozlem Oruc ◽

...

Keyword(s):

Lung Carcinoma ◽

Advanced Stage ◽

Cell Lung Carcinoma ◽

Nonsmall Cell Lung Carcinoma

Download Full-text

Abstract No. 78: Computed Tomography Guided Radiofrequency Ablation in the Management of Inoperable Primary Non-Small Cell Lung Carcinoma - Its Effect on Quality of Life and Survival

Journal of Vascular and Interventional Radiology ◽

10.1016/j.jvir.2008.12.067 ◽

2009 ◽

Vol 20 (2) ◽

pp. S31

Author(s):

N.G. Babu ◽

A.S. Bhalla ◽

S. Thulkar ◽

S. Hari ◽

G. Rath ◽

...

Keyword(s):

Quality Of Life ◽

Computed Tomography ◽

Radiofrequency Ablation ◽

Lung Carcinoma ◽

Small Cell Lung Carcinoma ◽

Small Cell ◽

Small Cell Lung ◽

Cell Lung Carcinoma

Download Full-text

Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma

Cancer ◽

10.1002/cncr.11460 ◽

2003 ◽

Vol 98 (1) ◽

pp. 128-134 ◽

Cited By ~ 34

Author(s):

Federico Cappuzzo ◽

Giovanni Selvaggi ◽

Vanesa Gregorc ◽

Francesca Mazzoni ◽

Maura Betti ◽

...

Keyword(s):

Induction Chemotherapy ◽

Lung Carcinoma ◽

Stage Iiib ◽

Stage Iiia ◽

Cell Lung Carcinoma ◽

Nonsmall Cell Lung Carcinoma ◽

Unresectable Stage ◽

Bulky N2 ◽

Gemcitabine And Cisplatin

Download Full-text

Relationship between anemia, hypoalbuminemia, vitamin D deficiency and quality of life in advanced non-small cell lung carcinoma patients at tertiary hospital in Bali

International Journal of Advances in Medicine ◽

10.18203/2349-3933.ijam20214126 ◽

2021 ◽

Vol 8 (11) ◽

pp. 1644

Author(s):

I. B. P. Ekaruna ◽

Ketut Suryana ◽

Jasminarti D. K. ◽

N. W. Candrawati ◽

N. L. P. Eka Arisanti ◽

...

Keyword(s):

Quality Of Life ◽

Vitamin D ◽

Multivariate Analysis ◽

Vitamin D Deficiency ◽

Small Cell ◽

Advanced Lung Cancer ◽

Advanced Stage ◽

Cell Lung Carcinoma ◽

Nsclc Patients

Background: The main purpose of treatment in patients with advanced lung cancer is more emphasizing on prolonging survival and improving the patient's quality of life (QOL). Micronutrient deficiency has an impact on the patient's QOL. The purpose of this study was to analyse the relationship between biochemical parameters of nutrient deficiency with QOL in patients with advanced non-small cell carcinoma (NSCLC) at Sanglah hospital.Methods: A cross sectional study was conducted in Sanglah general hospital on March-June 2021. Hemoglobin, albumin, and 2.5 (OH) D levels were obtained from patient's serum. The participant’s QOL was measured with EQ-5D-3L questionnaire. Bivariate analysis using chi-square test or Fisher's exact test, and multivariate analysis using logistic regression.Results: A total of 80 participants were included in this study, and 55% had poor QOL. Seventy percent participants had anemia, 36.3% had hypoalbuminemia, and 26.3% had vitamin D deficiency. The QOL of patients with advanced stage NSCLC was significantly associated with hypoalbuminemia (p=0.000) and vitamin D deficiency (p=0.044). Multivariate analysis showed that the most influential factor on the QOL of patients with advanced stage NSCLC was hypoalbuminemia (AOR 9.158; 95% CI 2.150-30.001; p=0.003).Conclusions: Hypoalbuminemia and vitamin D deficiency were significantly related with QOL of advance NSCLC patients. No relationship was found between anemia and the QOL of advance NSCLC patients. Hypoalbuminemia was the most influential factors related to the QOL of advance NSCLC patients.

Download Full-text

P578Multipoint pacing in cardiac resynchronization therapy - how to improve remodeling criteria and its impact in quality of life

EP Europace ◽

10.1093/europace/euaa162.085 ◽

2020 ◽

Vol 22 (Supplement_1) ◽

Author(s):

A Nunes Ferreira ◽

P S Antonio ◽

I Aguiar-Ricardo ◽

T Rodrigues ◽

N Cunha ◽

...

Keyword(s):

Quality Of Life ◽

Response Rate ◽

Reverse Remodeling ◽

Resynchronization Therapy ◽

Rate Reduction ◽

Systolic Volume ◽

End Systolic Volume ◽

The Impact

Abstract Background Despite the reduction in mortality and hospitalization rates, resynchronization therapy still has 30-40% of non-responders. Several studies are ongoing to evaluate if novel programming techniques such as multipoint pacing (MPP) increase the conversion rate of non-responder to responder to CRT. However, there is still lack of information about conversion to super-responders and the impact in quality of life of MPP. Purpose To evaluate the impact of MPP in conversion to super-responders and its impact in the quality of life of patients. Methods Randomized clinical trial of non-AF patients with indication for CRT and who implanted the Quartet™ quadripolar left ventricle (LV) lead. After implant, CRTs were programmed on biventricular pacing according to the latest activated area for 6 months. After a 6-month follow-up, patients were randomized in a 1:1 fashion to MPP ON or MPP OFF. MPP was programmed with the two widest spaced LV electrodes and with a LV1-LV2 to LV2-RV delay of 5ms. Patients were followed-up for 12 months with a 6-month evaluation of NTproBNP, echocardiographic remodeling criteria (LV end systolic volume (ESV) and LV ejection fraction), and quality of life (QoL) evaluated by EQ-5D, Minnesota Living with Heart Failure (MLWHF) questionnaire and 6-minute walk test (6MWT). Results 76 patients were included in this trial, 62 with a completed 12-month follow-up (average age 67.2 ± 10.2 years old, 32.3% female gender, dilated cardiomyopathy in 77.4%). Among these patients, 24 were randomized to MPP ON, 28 to MPP OFF. Six patients died and 4 were lost to follow-up. Baseline clinical and echocardiographic characteristics were similar between groups (p = NS). At 6 months, the overall response rate (reduction in ESV≥15%) was 75%. At twelve months, patients randomized to MPP ON had a super-response rate (reduction in ESV≥30%) higher than patients with MPP OFF (75% vs 39.3%, p = 0.01). Between 6-12 months, patients assigned to MPP ON had a higher reduction in ESV (93.4 ± 52.3mL to 82.1 ± 40.5mL, p = 0.04) and an improvement in LVEF (38.3 ± 9.8% to 45.1 ± 11.1%, p < 0.01) compared to patients with MPP OFF (92.2 ± 47.3mL to 95.4 ± 47.5mL, p = NS; 37.1 ± 12.0% to 40.2 ± 9.2%, p = NS). Additionally, QoL of patients with MPP ON improved during follow up (EQ-5D 78.3% to 86.3%, p < 0.01; MLWHF 12.1 to 6.6, p = 0.03, 6MWT 316m to 239m, p = NS; NTproBNP 1608 ± 2450pg/mL to 775 ± 914pg/mL, p = NS) and was unchanged in MPP OFF patients (76.6% to 74.2%; MLWHF 12.7 to 12.7; 6MWT 338m to 299m, NTproBNP 1112 ± 1442pg/mL to 1383 ± 2118pg/mL, for all p = NS). Conclusion In our population, patients with CRT programmed with MPP ON, when compared to MPP OFF, had an improvement in the super-response rate and in quality of life. These results may be consequence from a more favorable reverse remodeling due to MPP, with a higher reduction in the LV end systolic volume. Abstract Figure.

Download Full-text

Nonmotor Symptoms in Early- and Advanced-Stage Parkinson’s Disease Patients on Dopaminergic Therapy: How Do They Correlate with Quality of Life?

ISRN Neurology ◽

10.1155/2014/587302 ◽

2014 ◽

Vol 2014 ◽

pp. 1-4 ◽

Cited By ~ 12

Author(s):

Peter Valkovic ◽

Jan Harsany ◽

Marta Hanakova ◽

Jana Martinkova ◽

Jan Benetin

Keyword(s):

Quality Of Life ◽

Parkinson’S Disease ◽

Parkinson's Disease ◽

Early Stage ◽

Advanced Stage ◽

Nonmotor Symptoms ◽

Related Quality ◽

Attention Memory ◽

The Impact

To determine the impact of nonmotor symptoms (NMS) on health-related quality of life (HRQoL) we examined 100 Parkinson’s disease (PD) patients on dopaminergic medications. An “early-stage” (ES) and an “advanced-stage” (AS) groups were formed. HRQoL was established by the questionnaire PDQ-8, number of NMS by NMSQuest, and severity and frequency of NMS by the assessment scale NMSS. The total NMS averaged 11.3 (ES=9.6, AS=12.8). The NMSS domain correlation profiles for ES and AS did not fundamentally differ; however, the domains attention/memory and mood/apathy correlated moderately to strongly with HRQoL in ES, while the sleep/fatigue domain correlated moderately with HRQoL in AS. Weakly correlating domains were sleep/fatigue in ES and cardiovascular, attention/memory, and mood/apathy domains in AS. In view of these findings we strongly recommend systematic, active screening and therapy for neuropsychiatric disorders (mood, cognitive and sleep disorders, and fatigue) at the initial diagnosis and throughout the entire course of PD.

Download Full-text